815 related articles for article (PubMed ID: 27094481)
1. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
2. Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study.
Winship AL; Willson C; Hansen KR; Hutt KJ; Hickey M
BMJ Open; 2019 Nov; 9(11):e033810. PubMed ID: 31772111
[TBL] [Abstract][Full Text] [Related]
3. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
4. Assessment of ovarian reserve and reproductive outcomes in
Ponce J; Fernandez-Gonzalez S; Calvo I; Climent M; Peñafiel J; Feliubadaló L; Teulé A; Lázaro C; Brunet JM; Candás-Estébanez B; Durán Retamal M
Int J Gynecol Cancer; 2020 Jan; 30(1):83-88. PubMed ID: 31780568
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in women.
Verdiesen RMG; van der Schouw YT; van Gils CH; Verschuren WMM; Broekmans FJM; Borges MC; Gonçalves Soares AL; Lawlor DA; Eliassen AH; Kraft P; Sandler DP; Harlow SD; Smith JA; Santoro N; Schoemaker MJ; Swerdlow AJ; Murray A; Ruth KS; Onland-Moret NC
Hum Reprod; 2022 May; 37(5):1069-1082. PubMed ID: 35274129
[TBL] [Abstract][Full Text] [Related]
6. Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study.
Denis-Laroque L; Drouet Y; Plotton I; Chopin N; Bonadona V; Lornage J; Salle B; Lasset C; Rousset-Jablonski C
Breast; 2021 Oct; 59():239-247. PubMed ID: 34304065
[TBL] [Abstract][Full Text] [Related]
7. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
[TBL] [Abstract][Full Text] [Related]
8. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study.
Bell RJ; Islam RM; Skiba MA; Herbert D; Martinez Garcia A; Davis SR
Hum Reprod; 2021 Dec; 37(1):109-118. PubMed ID: 34741176
[TBL] [Abstract][Full Text] [Related]
9. FSHB -211 G>T is a major genetic modulator of reproductive physiology and health in childbearing age women.
Rull K; Grigorova M; Ehrenberg A; Vaas P; Sekavin A; Nõmmemees D; Adler M; Hanson E; Juhanson P; Laan M
Hum Reprod; 2018 May; 33(5):954-966. PubMed ID: 29617818
[TBL] [Abstract][Full Text] [Related]
10. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
[TBL] [Abstract][Full Text] [Related]
11. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation.
Gunnala V; Fields J; Irani M; D'Angelo D; Xu K; Schattman G; Rosenwaks Z
Fertil Steril; 2019 Feb; 111(2):363-371. PubMed ID: 30527950
[TBL] [Abstract][Full Text] [Related]
12. Serum anti-Müllerian hormone concentration and follicle density throughout reproductive life and in different diseases-implications in fertility preservation.
Liebenthron J; Reinsberg J; van der Ven K; Saenger N; Kruessel JS; von Wolff M
Hum Reprod; 2019 Dec; 34(12):2513-2522. PubMed ID: 31782794
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic review of the literature.
Merlino L; Chiné A; Galli C; Piccioni MG
Minerva Ginecol; 2020 Oct; 72(5):339-348. PubMed ID: 32744451
[TBL] [Abstract][Full Text] [Related]
14. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA;
Eur J Cancer; 2017 Oct; 84():114-120. PubMed ID: 28802188
[TBL] [Abstract][Full Text] [Related]
15. Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis.
Cordeiro Mitchell CN; McGuinness B; Fine E; Kearns WG; Christianson MS; Segars J; Pastore LM
J Assist Reprod Genet; 2020 May; 37(5):1037-1055. PubMed ID: 32212026
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD.
Derks-Smeets IAP; van Tilborg TC; van Montfoort A; Smits L; Torrance HL; Meijer-Hoogeveen M; Broekmans F; Dreesen JCFM; Paulussen ADC; Tjan-Heijnen VCG; Homminga I; van den Berg MMJ; Ausems MGEM; de Rycke M; de Die-Smulders CEM; Verpoest W; van Golde R
J Assist Reprod Genet; 2017 Nov; 34(11):1475-1482. PubMed ID: 28831696
[TBL] [Abstract][Full Text] [Related]
17. Discordance between serum anti-Müllerian hormone concentrations and antral follicle counts: not only technical issues.
Alebic MŠ; Stojanovic N; Dewailly D
Hum Reprod; 2018 Jun; 33(6):1141-1148. PubMed ID: 29688494
[TBL] [Abstract][Full Text] [Related]
18. The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status.
C E DK; C VTT; J C EM; G W M LE; Irene H; Mariette G; J T VGR; Willem V; D LK; J M BF; M E BA
Reprod Sci; 2023 Jan; 30(1):270-282. PubMed ID: 35705781
[TBL] [Abstract][Full Text] [Related]
19. Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing.
Iliodromiti S; Salje B; Dewailly D; Fairburn C; Fanchin R; Fleming R; Li HWR; Lukaszuk K; Ng EHY; Pigny P; Tadros T; van Helden J; Weiskirchen R; Nelson SM
Hum Reprod; 2017 Aug; 32(8):1710-1715. PubMed ID: 28854583
[TBL] [Abstract][Full Text] [Related]
20. Anti-Mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro.
Rosario R; Stewart HL; Spears N; Telfer EE; Anderson RA
Hum Reprod; 2024 Feb; 39(2):382-392. PubMed ID: 38070496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
